![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
20
Shilpa Medicare Limited Raichur In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Ticlopidine hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2005-004 - Rev 00
This Chemical Type CEP, issued on February 21, 2011, remains in force until September 29, 2016, ensuring its reliability within the pharmaceutical industry.
Substance Number 1050 associated with this CEP further emphasizes